This product is a long-acting tricyclic antihistamine that can relieve seasonal allergic rhinitis or non-nasal symptoms by selectively antagonizing peripheral H1 receptors.

It can reduce the increase of serum AST and ALT in the animal acute liver injury model caused by TAA (thioacetamide) and CC14 (carbon tetrachloride), and inhibit the accumulation of triglycerides caused by chronic liver injury model; it can promote liver glycogen synthesis, inhibit the increase of cholesterol, and help to restore the serum albumin/globulin ratio.

This product belongs to the third generation of cephalosporin, with broad-spectrum antibacterial effect, and is stable to the broad-spectrum beta-lactamase produced by various Gram-positive and Gram-negative bacteria. It has a strong antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Pseudomonas and Acinetobacter species such as Pseudomonas aeruginosa are less sensitive to this product. It has a good antibacterial effect on Haemophilus influenzae and Neisseria gonorrhoeae. The effect on Staphylococcus aureus and Staphylococcus epidermidis is worse than that of the first and second generation cephalosporins. Methicillin-resistant Staphylococcus aureus and Enterococcus are resistant to this product, and various streptococci are highly sensitive to this product. Anaerobic bacteria such as Peptococcus, Peptostreptococcus and some Bacteroides are mostly sensitive to this product, and Clostridium difficile is resistant to this product. The bactericidal effect is achieved by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

No specific pharmacological effects mentioned